Relationships between properties of 131I-therapy capsules and the radioiodine kinetics;Zusammenhange zwischen Eigenschaften von 131I-Therapiekapseln und der Radioiodkinetik

NuklearMedizin

Volumn 35, Issue 5, 1996, Pages 175-180

  Schomacker K ^a,c   Wellner, U ^a   Scheidhauer, K ^a   Gabruk Szostak, B ^a   Fischer, T ^a   Steinbach, J ^b   Fuchtner F ^b   Schicha, H ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

capsules; iodine 131; non radioactive iodine; therapy; thyroid

Indexed keywords

IODINE; IODINE 131; RADIOACTIVE IODINE;

ARTICLE; CONTROLLED STUDY; DRUG QUALITY; ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; RADIOISOTOPE THERAPY; COLORIMETRY; HUMAN; MICROCAPSULE; SOLUBILITY;

CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORIMETRY; ELECTROPHORESIS, CELLULOSE ACETATE; HUMANS; IODINE RADIOISOTOPES; SOLUBILITY;

EID: 0030254090     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629804     Document Type: Article

References (33)

1. Anghileri LJ. Reduction of iodate and periodate by rat tissues in vitro. Naturwissenschaften 1965; 52: 396.
2. Anghileri LJ. Fate of intravenously injected iodate and periodate. Biochem Phannacol 1965; 14: 1930-4.
3. Bernstein R, Haugen HF, Frey H. Thyroid function during erythrosine ingestion in doses encountered in therapy with conventional antibodies. Scand J Clin Lab Invest 1975; 35: 49-52.
4. Bora S, Radichevich J, Werner SC. Artificial elevation of PBI from an iodinated dye used to stain medical capsules pink. J clin Endocr Metab 1969; 29: 1269-71.
5. Chrysochoos J, Shihabi DS. X-radiolysis of aqueous erythrosine. Radiat Res 1971; 47: 392-401.
6. Clements FW, Gibson HB, Howeller-Coy JF. Goitre prophylaxis by addition of potassium iodate to bread (experience in Tasmania). Lancet 1970; 1: 459-92
7. Cronquist A, Pochin EE, Thompson BD. The speed of suppression by iodate of thyroid iodine uptake. Health Phys 1971; 21: 393-4.
8. DeNardo GL. In: Medical Radionuclide Imaging. 1977; vol 2, IAEA-SM, 210/308, IAEA, Vienna, Austria: 3-20.
9. Dewanjee MK. Radioiodination: Theory, Practice, and Biomedical Application. Boston, Dordrecht, London: Kluwer Academic Publishers 1992.
10. Evans EA. Self-decomposition of radiochemicals: principles, control, observations and effects. Amersham Cooperation, Arlington Heights, IL: Review February 1976; 16; cited in: Dewanjee MK. Radioiodination: Theory, Practice, and Biomedical Application. Boston, Dordrecht, London: Kluwer Academic Publishers 1992, p. 604.
11. Evans EA. Self-decomposition of radiochemicals: principles, control, observations and effects. Amersham Cooperation, Arlington Heights, IL: Review February 1976; 16; cited in: Dewanjee MK. Radioiodination: Theory, Practice, and Biomedical Application. Boston, Dordrecht, London: Kluwer Academic Publishers 1992, p. 604.
12. Füchtner F. Aufbau und Erprobung eines HPLC-Meßplatzes zur Ionenchromatographie für den KKW-Betrieb. 1988; interner Bericht.
13. Gabriel R, Grimm I, Hoffmann H. Internal processing of iodate. Z Gesamte Hyg 1985; 31: 363-5.
14. Gardner DF, Utiger RD, Schwartz SL, Witorsch P, Meyers B, Braverman LE, Witorsch RJ. Effects of oral erythrosine (2′, 4′, 5′, 7′-tetraiodofluorescein) on thyroid function in normal men. Toxicol Appl Pharmacol 1987; 91: 299-304.
15. Haas S. Contamination of protein bound iodine by pink gelatine capsules colored with erythrosine. Ann Intern Med 1970; 72: 549-52.
16. Haid H. The time course of radioiodine distribution in chicks after iodate treatment. Endokrinologie 1975; 66: 319-23.
17. Hansen WH, Zwickey RE, Brouwer JB, Fitzhugh OG. Long term toxicity studies of erythrosine. I. Effects in rats and dogs. Food Cosmet Toxicol 1973; 11: 527-34.
18. Ill'in LA, Akrhangel'skaya GV, Konstantinov YU, Likhtarev IA. Radioactive iodine in the problem of nuclear safetey. In: Springfield IA ed. NTIS US Atomic Energy Commission translation. 1972; TR-7536: 222-35.
19. Jennings AS, Schwartz SL, Balter NJ, Gardner DF, Witorsch RJ. Effects of oral erythrosine (2′, 4′, 5′, 7′-tetraiodofluorescein) on the pituitary-thyroid axis in rats. Toxicol Appl Pharmacol 1990; 103: 549-56.
20. Langer P, Tajtakova M. The importance of optimal iodine intake, the present status and perspectives in Slovakia. Vnitr Lek 1992; 38: 845-9.
21. Matovinovic J, Ramlingaswami V. Therapy and prophylaxis of endemic goiter. In: Endemic Goiter. Geneva; World Health Organization: 385-410.
22. 131J bei der Radiojodbehandlung benigner Schilddrüsenerkrankungen. Nuklearmedizin 1991; 30: 71-6.
23. Nüchel C, Boddenberg B, Schicha H. Die Bedeutung des Radioiodtests für die Berechnung der Therapiedosis bei benignen Schilddrüsenerkrankungen. Nuklearmedizin 1993; 32: 91-8.
24. 131I uptake by the thyroid in rats. Health Phys 1993; 65: 545-9.
25. Römpp Chemie Lexikon. Falbe J, Regitz M (Hrsg). Stuttgart, New York: Georg Thieme Verlag 1991; Band 4 M-Pk: S. 2895.
26. Ruiz M, Ingbar S. Effect of erythrosine (2′, 4′, 5′, 7′-tetraiodofluorescein) on the metabolism of thyroxine in rat liver. Endocrinology 1982; 110: 1613-17.
27. Schicha H, Scheidhauer K. Therapie mit offenen radioaktiven Stoffen. In: Nuklearmedizin. Büll U, Schicha H, Biersack HJ, Knapp WH, Reiners C, Schober O, Hrsg. Stuttgart, New York: Georg Thieme Verlag 1994: 460-87.
28. 131I-Therapiekapseln und der Radioiodkinetik. Nuklearmedizin 1995; 34: A119.
29. Taurog A, Howells EM, Nachimson HI. Conversion of iodate to iodide in vivo and in vitro. J Biol Chem 1966; 241: 4686-93.
30. Vought RL, Brown FA, Wolff J. Erythrosine: An advantitious source of iodide. J Clin Endocrin 1972; 34: 747-52.
31. Wawschinek O, Eber O, Petek W, Wakönig P, Gürakar A. Bestimmung der Harniodausscheidung mittels einer modifizierten Cer-Arsenit-Methode. Berichte OGKC. 1985; 8: 13-5.
32. Wellner U, Schomäcker K, Schicha H. Possible explanation for discrepancies in the kinetics of I-131 either for diagnostic or therapeutic purposes. Eur J Nucl Med 1995; 22: 778 (Abstract).
33. 131J-Kinetik unter Test und Therapie bei benignen Schilddrüsenerkrankungen. Nuklearmedizin 1990; 2: A67, P42.